152 related articles for article (PubMed ID: 32950556)
21. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
22. Individual and combined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats.
Xu DD; Mo ZX; Yung KK; Yang Y; Leung AW
Neurosignals; 2006-2007; 15(6):322-31. PubMed ID: 18437031
[TBL] [Abstract][Full Text] [Related]
23. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects.
Hallak JE; Dursun SM; Bosi DC; de Macedo LR; Machado-de-Sousa JP; Abrão J; Crippa JA; McGuire P; Krystal JH; Baker GB; Zuardi AW
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):198-202. PubMed ID: 21062637
[TBL] [Abstract][Full Text] [Related]
24. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.
Rodríguez-Muñoz M; Onetti Y; Cortés-Montero E; Garzón J; Sánchez-Blázquez P
Mol Brain; 2018 Sep; 11(1):51. PubMed ID: 30223868
[TBL] [Abstract][Full Text] [Related]
25. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis.
de Bartolomeis A; Sarappa C; Buonaguro EF; Marmo F; Eramo A; Tomasetti C; Iasevoli F
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():1-12. PubMed ID: 23800465
[TBL] [Abstract][Full Text] [Related]
26. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.
Sonego AB; Gomes FV; Del Bel EA; Guimaraes FS
Behav Brain Res; 2016 Aug; 309():22-8. PubMed ID: 27131780
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
29. The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia.
Mahmoud GS; Hosny G; Sayed SA
Int J Physiol Pathophysiol Pharmacol; 2021; 13(2):22-35. PubMed ID: 34093963
[TBL] [Abstract][Full Text] [Related]
30. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.
Valvassori SS; Elias G; de Souza B; Petronilho F; Dal-Pizzol F; Kapczinski F; Trzesniak C; Tumas V; Dursun S; Chagas MH; Hallak JE; Zuardi AW; Quevedo J; Crippa JA
J Psychopharmacol; 2011 Feb; 25(2):274-80. PubMed ID: 19939866
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.
Duncan GE; Leipzig JN; Mailman RB; Lieberman JA
Brain Res; 1998 Nov; 812(1-2):65-75. PubMed ID: 9813244
[TBL] [Abstract][Full Text] [Related]
32. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.
Gomes FV; Del Bel EA; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():43-7. PubMed ID: 23791616
[TBL] [Abstract][Full Text] [Related]
33. Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
Thériault RK; St-Denis M; Hewitt T; Khokhar JY; Lalonde J; Perreault ML
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073710
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.
Pedrazzi JF; Issy AC; Gomes FV; Guimarães FS; Del-Bel EA
Psychopharmacology (Berl); 2015 Aug; 232(16):3057-65. PubMed ID: 25943166
[TBL] [Abstract][Full Text] [Related]
35. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia.
Becker A; Peters B; Schroeder H; Mann T; Huether G; Grecksch G
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):687-700. PubMed ID: 12787858
[TBL] [Abstract][Full Text] [Related]
36. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
Levin R; Almeida V; Peres FF; Calzavara MB; da Silva ND; Suiama MA; Niigaki ST; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
Curr Pharm Des; 2012; 18(32):4960-5. PubMed ID: 22716146
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS
Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539
[TBL] [Abstract][Full Text] [Related]
38. Interactions between cannabidiol and Δ
Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
[TBL] [Abstract][Full Text] [Related]
39. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine.
Duncan GE; Miyamoto S; Leipzig JN; Lieberman JA
Brain Res; 1999 Oct; 843(1-2):171-83. PubMed ID: 10528123
[TBL] [Abstract][Full Text] [Related]
40. Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly I:C rat model of schizophrenia.
Jimenez Naranjo C; Osborne AL; Weston-Green K
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109640. PubMed ID: 31108177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
